Pramana Pharmaceuticals Inc.
is an early-stage pharmaceutical company focused on the development of novel therapeutics based on small molecule platforms
The Company’s lead product
in its pipeline is an innovative GPR119 agonist based treatment for Type 2 Diabetes Mellitus (“T2DM”) and other Metabolic disorders including Obesity.
The Company has focused on, and successfully achieved, the creation of a new chemical class based on its novel design strategy.
Unlocking The Power of Therapeutic Compounds
Advancing the potential of a novel activation of the Pancreas
GPR119 is a G protein-coupled receptor expressed predominantly in the pancreas (β-cells) and gastrointestinal tract (enteroendocrine cells) in humans. In vitro studies have indicated a role for GPR119 in the modulation of insulin release by pancreatic β-cells and of glp-1, gip and pyy secretion by gut enteroendocrine cells.
Proprietary Technology Platform
Overseen by a world class scientific team, Pramana has utilized their expertise in the development of its potent, selective and proprietary wholly owned GPR119 portfolio.
Pramana's Proprietary Pipeline
Development is 100% funded by the founders
Pramana‘s corporate structure was designed with a goal of establishing a robust pipeline through preclinical research conducted in a highly innovative and cost-effective manner.
Recent Pre-Clinical Licensing Deals:
Merck acquires NGM Bio's preclinical pipeline target Diabetes Nash and Obesity for $450 million and a $94 million
Eli Lilly acquires Aurka Pharma compound AK-01 cancer target for $735 million with a $110 million
Eli Lilly acquires Silicon Therapeutics Inc compound target Type 1 Diabetes for $473 million with a $63 million
Celgene acquires TRPH-395 small molecule cancer target for $940 million with a $40 million upfront payment
Eli Lilly acquires Chugai's Owl833 GLP1 agonist compound target Type 2 Diabetes for undisclosed milestones with a $50 million upfront payment
The market is shifting
The market is shifting from Insulin based drugs to non-insulin-based treatments. By 2023, the top 10 products which are expected to occupy more than 40% of the market will be non-insulin products.